Pfizer (PFE) is trading at $26.59 with shares up 9.31% year-to-date, while Guggenheim raised its price target to $36 with a Buy rating versus Wall Street’s cautious $28.14 consensus. Pfizer’s oncology ...

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study made it hard to determine how well it works on a ...

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, a lackluster result as fewer-than-expected infections in the pivotal study made its potency ...

Pfizer and Valneva said Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal. Subscribe to read this story ad-free Get unlimited ...

Pharmaceutical giant Pfizer PFE1.28%increase; green up pointing triangle and French vaccine maker Valneva VLA 0.29%increase; green up pointing triangle reported positive topline results from their ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...

As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. The Ignite ...

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weight loss and erectile dysfunction — two ...

(RTTNews) - Pfizer Inc. (PFE) on Friday said the U.S. Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Application (sBLA) for HYMPAVZI.

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...